Details of patients with WM in this study
| Patient . | Sex/age, y . | Paraprotein isotype . | IgM, g/L . | TCRVβ clone expanded . | TCRVβ as % of CD3 cells . | Previous nucleoside analogue therapy . | Transformed to NHL . |
|---|---|---|---|---|---|---|---|
| 1 | F/77 | IgM L | 14.6 | 22 | 9.2 | N | N |
| 2 | M/85 | IgM K | 37.1 | 17 | 11.7 | N | N |
| 3 | F/89 | IgM K | 20.1 | 2 | 17.8 | Y | N |
| 3 | 14.1 | ||||||
| 5.1 | 9.3 | ||||||
| 4 | F/88 | IgM K | 22.5 | 20 | 21 | N | N |
| 5 | F/82 | IgM K | 32.1 | 21.3 | 8 | N | N |
| 6 | M/83 | IgM L | 17.4 | 3 | 9.7 | N | N |
| 13.6 | 6.3 | ||||||
| 23 | 4.4 | ||||||
| 7 | M/76 | IgM K | 16.8 | 3 | 27.4 | N | N |
| 8 | M/86 | IgM K | 21.4 | 5.1 | 9.9 | N | N |
| 9 | M/86 | IgM L | 13.8 | 22 | 4.2 | N | N |
| 10 | M/76 | IgM K | 20.9 | 17 | 44 | N | N |
| 11 | F/79 | IgM L | 24.4 | 5.1 | 8.0 | N | N |
| 23 | 4.0 | ||||||
| 12 | F/71 | IgM K | 42.2 | 9 | 18.9 | N | N |
| 13.1 | 20.4 | ||||||
| 13 | M/58 | IgM K | 22.9 | 7 | 5.1 | N | N |
| 14 | M/75 | IgM K | 40.8 | 5.1 | 8.5 | N | N |
| 15 | M/86 | IgM L | 2.7 | None | NA | Y | Y |
| 16 | M/68 | IgM K | 2.0 | None | NA | Y | N |
| 17 | M/71 | IgM K | 27.0 | None | NA | Y | N |
| 18 | F/64 | IgM K | 0.3 | None | NA | Y | N |
| 19 | M/75 | IgM L | 26.2 | None | NA | Y | N |
| 20 | M/69 | IgM L | 11.6 | None | NA | N | N |
| Patient . | Sex/age, y . | Paraprotein isotype . | IgM, g/L . | TCRVβ clone expanded . | TCRVβ as % of CD3 cells . | Previous nucleoside analogue therapy . | Transformed to NHL . |
|---|---|---|---|---|---|---|---|
| 1 | F/77 | IgM L | 14.6 | 22 | 9.2 | N | N |
| 2 | M/85 | IgM K | 37.1 | 17 | 11.7 | N | N |
| 3 | F/89 | IgM K | 20.1 | 2 | 17.8 | Y | N |
| 3 | 14.1 | ||||||
| 5.1 | 9.3 | ||||||
| 4 | F/88 | IgM K | 22.5 | 20 | 21 | N | N |
| 5 | F/82 | IgM K | 32.1 | 21.3 | 8 | N | N |
| 6 | M/83 | IgM L | 17.4 | 3 | 9.7 | N | N |
| 13.6 | 6.3 | ||||||
| 23 | 4.4 | ||||||
| 7 | M/76 | IgM K | 16.8 | 3 | 27.4 | N | N |
| 8 | M/86 | IgM K | 21.4 | 5.1 | 9.9 | N | N |
| 9 | M/86 | IgM L | 13.8 | 22 | 4.2 | N | N |
| 10 | M/76 | IgM K | 20.9 | 17 | 44 | N | N |
| 11 | F/79 | IgM L | 24.4 | 5.1 | 8.0 | N | N |
| 23 | 4.0 | ||||||
| 12 | F/71 | IgM K | 42.2 | 9 | 18.9 | N | N |
| 13.1 | 20.4 | ||||||
| 13 | M/58 | IgM K | 22.9 | 7 | 5.1 | N | N |
| 14 | M/75 | IgM K | 40.8 | 5.1 | 8.5 | N | N |
| 15 | M/86 | IgM L | 2.7 | None | NA | Y | Y |
| 16 | M/68 | IgM K | 2.0 | None | NA | Y | N |
| 17 | M/71 | IgM K | 27.0 | None | NA | Y | N |
| 18 | F/64 | IgM K | 0.3 | None | NA | Y | N |
| 19 | M/75 | IgM L | 26.2 | None | NA | Y | N |
| 20 | M/69 | IgM L | 11.6 | None | NA | N | N |
WM indicates Waldenström macroglobulinemia; TCRVβ, T-cell receptor Vβ; NHL, non-Hodgkin lymphoma; None, no TCRVβ clone; NA, not applicable; Y, yes; and N, no.